Alkermes plc
ALKS
Hisse Senetlerindeki Sıralama
#2631
Alkermes plc, a biopharmaceutical company, engages in the research,... Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Hisse Fiyatı
$43.05
Son senkronizasyon: 2026-10-19
Piyasa Değeri
$7.22B
Değişim (1 gün)
4.43%
Değişim (1 yıl)
38.95%
Ülke
IE
Ticaret Alkermes plc (ALKS)
Kategori
Healthcare
Alkermes plc (ALKS) için gelir
Jun 2026 itibarıyla gelir TTM: $1.67B
Alkermes plc şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) $1.67B'dir. 2023 yılında şirketin geliri $1.66B önceki yıla göre artış 2022 yılındaki $1.11B gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Alkermes plc için 2000 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
| Yıl | Gelir | Değiştir |
|---|---|---|
| 2026 (TTM) | $1.67B | 7.06% |
| 2024 | $1.56B | -6.36% |
| 2023 | $1.66B | 49.61% |
| 2022 | $1.11B | -5.28% |
| 2021 | $1.17B | 13.00% |
| 2020 | $1.04B | -11.29% |
| 2019 | $1.17B | 7.01% |
| 2018 | $1.09B | 21.13% |
| 2017 | $903.37M | 21.15% |
| 2016 | $745.69M | 18.68% |
| 2015 | $628.34M | 1.54% |
| 2014 | $618.79M | 7.51% |
| 2013 | $575.55M | 0.00% |
| 2012 | $575.55M | 47.59% |
| 2011 | $389.98M | 108.95% |
| 2010 | $186.64M | 4.69% |
| 2009 | $178.28M | -45.45% |
| 2008 | $326.84M | 35.78% |
| 2007 | $240.72M | 0.31% |
| 2006 | $239.97M | 44.04% |
| 2005 | $166.60M | 118.85% |
| 2004 | $76.13M | 94.92% |
| 2003 | $39.05M | -17.37% |
| 2002 | $47.27M | -12.63% |
| 2001 | $54.10M | -3.44% |
| 2000 | $56.03M | 0.00% |
Benzer şirketler veya rakiplerin geliri
| Şirket | Gelir | Gelir Farkı | Ülke |
|---|---|---|---|
| $12.62B | 657.01% |
US
|
|
| $2.23B | 33.60% |
US
|
|
| $15.74B | 844.10% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 261.06% |
NL
|
